Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602303 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Torsemide Tablets Under Fasting Conditions
A NA study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT00602303 is a NA study that has completed, run by Roxane Laboratories. The registered enrollment target is 28 participants.
The verdict
NCT00602303, a NA study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.
Interventions
- DRUG Torsemide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2003-09 |
| Est. Completion | 2003-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00602303
The ClinicalTrials.gov registry entry for NCT00602303 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Torsemide is the first listed.
NCT00602303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00602303 about?
NCT00602303 is a clinical study titled "Bioequivalency Study of Torsemide Tablets Under Fasting Conditions". The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.
What is the current status of trial NCT00602303?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2003-09. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00602303?
The interventions under investigation include: Torsemide (DRUG).
Who is sponsoring clinical trial NCT00602303?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.